ÂÜÀòÂÒÂ×

Nicholas (Nic) Dracopoli, Ph.D. is Chief Scientific Officer at a seed stage cancer diagnostics company based in Baltimore, MD, and he also serves as a consultant to several other early stage diagnostic and oncology companies. Previously he was Senior Vice President of Translational Sciences at Personal Genome Diagnostics (PGDx). For the prior eighteen years, he served in leadership oncology drug development roles at Bristol Myers-Squibb (BMS) and Janssen Pharmaceuticals. In these roles, he was responsible for building two new translational science teams whose work contributed to the approval of several new oncology drugs. Prior to leaving Janssen Nic was Vice President, Head of Oncology Diagnostics and Vice President, Head of Oncology Translation Research.

Before joining the pharmaceutical industry, he spent five years in the biotechnology industry at Sequana Therapeutics. Nic obtained his bachelor’s degree and doctorate from the University of London and completed post-doctoral fellowships at the Memorial Sloan-Kettering Cancer Center in New York City, NY and the Massachusetts Institute of Technology (MIT) in Cambridge, MA. Subsequently, he served as an Assistant Director at the Whitehead/MIT Genome Center and as a Section Chief at the National Center for Human Genome Research at the National Institutes of Health, Bethesda, MD. Nic has authored more than 70 scientific publications and has extensive experience in the fields of genomics, molecular biology and cancer research.